A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease

Trial Profile

A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2018

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Community-acquired pneumonia; Pneumococcal infections
  • Focus Therapeutic Use
  • Acronyms CAPiTA
  • Sponsors Pfizer
  • Most Recent Events

    • 31 May 2018 Results of post hoc analysis evaluating efficacy published in the Vaccine
    • 22 May 2018 Results published in the Media Release
    • 08 Feb 2018 Results (n=84064) of post hoc analysis assessing the efficacy of the 13 valent pneumococcal conjugate vaccine (PCV13) in adults aged more than or equal to 65 years with at risk conditions published in the Vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top